The key contents of the Chinese instruction manual of Ordesibat (Belvi) and the correct method of taking it

Odevixibat (trade name: Bei Erwei) is a new type of small molecule drug, mainly used to treat chronic liver diseases caused by bile acid accumulation, especially for familial cholestasis (PFIC) in children and adults. PFIC is an inherited liver disease caused by abnormal accumulation of bile acids in the liver and blood, leading to cholestasis, intractable itching, jaundice, and impaired liver function. Odesibat reduces bile acid reabsorption from the intestine by selectively inhibiting the small intestinal bile acid transporter (IBAT/OATP), thereby reducing blood and liver bile acid levels and improving patients' clinical symptoms. The emergence of this drug provides a new oral treatment method for this type of long-term and rapidly progressing liver disease, and is one of the clinical breakthrough drugs for PFIC and related diseases.

In terms of taking method, odexibat is usually provided as oral capsules or soluble powder, and the dosage needs to be individually adjusted according to the patient's age and weight. For pediatric patients, the generally recommended dose is approximately 0.5–1.0 mg per kilogram of body weight once a day; for adult patients, the dose should be adjusted appropriately based on physician evaluation and liver function status. Medications should be taken with or after meals, which not only helps improve drug absorption but also reduces gastrointestinal discomfort. If the patient has difficulty swallowing, the contents of the capsule can be dissolved in water or juice and taken, but they must be taken all at once to ensure complete absorption and efficacy of the drug. The correct method of taking medication is crucial to maintaining stable blood concentration and exerting sustained efficacy.

During use, the efficacy and safety of odexibat must be ensured through strict monitoring. Before treatment, patients need to undergo liver function tests, routine blood tests, and bile acid level measurements to establish baseline data. During medication, blood bile acid concentrations, liver function and potential adverse reactions, including diarrhea, nausea, abdominal pain or weight loss, should be regularly monitored. Clinical practice shows that some patients may experience mild to moderate diarrhea or digestive discomfort in the early stages, but most symptoms can be relieved with continued medication and dose adjustment. If serious adverse reactions occur, the doctor may recommend temporarily stopping the medication or adjusting the dose to ensure patient safety. In addition, patients taking long-term medication should review their liver function every 1–3 months in order to detect potential problems early and optimize the dose based on efficacy and tolerability.

The comprehensive medication management of odexibat not only relies on the drug itself, but also requires the active cooperation of patients and their families. While taking the medication, patients should maintain a low-fat diet to reduce bile acid production and liver burden; at the same time, regular work and rest and moderate exercise can also help improve the quality of life and drug efficacy. Parents or patients must strictly follow the doctor's instructions, take medication on time, avoid missing doses or adjust the dosage by themselves. If you miss a dose, you should take it as soon as you remember. However, if it is close to the next dose, you should skip it and do not take double doses at one time. Scientific drug management, regular review and individualized dose adjustment are the key to ensuring the treatment of odixibatPFICand related diseases is the key to safety and effectiveness. Overall, odexibat can not only significantly relieve patients' symptoms of itching and jaundice, but also delay disease progression and improve quality of life. It is an important treatment option for patients with chronic cholestatic liver disease.

Reference link:https://www.drugs.com